Advisory Services Network’s Atea Pharmaceuticals AVIR Stock Holding History

Advisory Services Network’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-200	Closed	-$670	–	1596
2023 Q1	$670	Hold	200	–	–	﹤0.01%	3690
2022 Q4	$962	Buy	+200	New	+$1.01K	﹤0.01%	3595
2021 Q3	–	Sell	-4,870	Closed	-$105K	–	1521
2021 Q2	$105K	Buy	+4,870	New	+$146K	﹤0.01%	1580

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Advisory Services Network's AVIR Position: Q2 2023 in Review

Advisory Services Network sold out of Atea Pharmaceuticals (AVIR) in Q2 2023, closing a stake of 200 shares — an estimated $670 sold.

Advisory Services Network first reported a position in AVIR in Q2 2021 and held it in 3 quarters. The position peaked at $105K in Q2 2021. 133 funds tracked by Wall St. Rank hold AVIR as of Q2 2023.

Advisory Services Network reported no remaining Atea Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Advisory Services Network sold 200 Atea Pharmaceuticals shares in Q2 2023, an estimated $670.
Advisory Services Network first reported a position in Atea Pharmaceuticals in Q2 2021 and held it in 3 quarters.
Advisory Services Network's Atea Pharmaceuticals position peaked at $105K in Q2 2021.
133 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2023.

Based on Advisory Services Network's 13F filing for Q2 2023, filed 9 Aug 2023.